Combination strategies for enhancing the efficacy of immunotherapy in cancer patients

Annals of the New York Academy of Sciences

Volumn 1194, Issue , 2010, Pages 169-178

  Moschella, Federica ^a   Proietti, Enrico ^a   Capone, Imerio ^a   Belardelli, Filippo ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Cancer; Chemoimmunotherapy; Cyclophosphamide; IFN alpha; Immunotherapy

Indexed keywords

ALPHA INTERFERON; ALPHA2B INTERFERON; BETA INTERFERON; CANCER VACCINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEPATITIS B VACCINE; MELACINE; MELANOMA VACCINE; PACLITAXEL; PEPTIDE VACCINE; THERATOPE; THYMOSIN ALPHA1; TUMOR ANTIGEN;

ACTIVE IMMUNIZATION; ADOPTIVE IMMUNOTHERAPY; ANTINEOPLASTIC ACTIVITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; DENDRITIC CELL; DRUG EFFICACY; DRUG MEGADOSE; DRUG POTENTIATION; EXPERIMENTAL MODEL; GENE EXPRESSION; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; NONHUMAN; SOLID TUMOR; TUMOR RESISTANCE; WHOLE BODY RADIATION;

ANIMALIA;

EID: 77951847280     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2010.05464.x     Document Type: Conference Paper

References (67)

1. Disis, M.L., H. Bernhard & E.M. Jaffee. 2009. Use of tumour-responsive T cells as cancer treatment. Lancet. 373: 673-683.
2. Rosenberg, S.A., J.C. Yang & N.P. Restifo. 2004. Cancer immunotherapy: moving beyond current vaccines. Nat. Med. 10: 909-915.
3. Galon, J. et al. 2006. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964.
4. Zou, W. 2006. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6: 295-307.
5. Nagaraj, S. & D.I. Gabrilovich. 2008. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res. 68: 2561-2563.
6. Wei, W.Z. et al. 2005.Concurrent induction of antitumor immunity and autoimmune thyroiditis in CD4+ CD25 +regulatory T cell-depleted mice. Cancer Res. 65: 8471-8478.
7. Phan,G.Q. et al. 2003.Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 100: 8372-8377.
8. Le Bon, A. & D.F. Tough. 2002. Links between innate and adaptive immunity via type I interferon. Curr. Opin. Immunol. 14: 432-436.
9. Belardelli, F. & I. Gresser. 1996. The neglected role of type I interferon in the T-cell response: implications for its clinical use. Immunol. Today 17: 369-372.
10. Ferrantini, M., I. Capone & F. Belardelli. 2007. Interferon-alpha and cancer: mechanisms of action and new perspectives of clinical use. Biochimie 89: 884-893.
11. Ferrantini, M. & F. Belardelli. 2000. Gene therapy of cancer with interferon: lessons from tumor models and perspectives for clinical applications. Semin. Cancer Biol. 10: 145-157.
12. Belardelli, F. et al. 1998. The induction of in vivo proliferation of long-lived CD44hi CD8+ T cells after the injection of tumor cells expressing IFN-alpha1 into syngeneic mice. Cancer Res. 58: 5795-5802.
13. Sikora, A.G. et al. 2009. IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. J. Immunol. 182: 7398-7407.
14. Santini, S.M. et al. 2000. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J. Exp. Med. 191: 1777-1788.
15. Santini, S.M. et al. 2009. IFN-alpha in the generation of dendritic cells for cancer immunotherapy. Handb. Exp. Pharmacol. 295-317.
16. Parlato, S. et al. 2001. Expression of CCR-7, MIP-3beta, and Th-1 chemokines in type I IFN-induced monocytederived dendritic cells: importance for the rapid acquisition of potent migratory and functional activities. Blood 98: 3022-3029.
17. Moschella, F. et al. 2003. Gene expression profiling and functional activity of human dendritic cells inducedwith IFN-alpha-2b: implications for cancer immunotherapy. Clin. Cancer Res. 9: 2022-2031.
18. Lapenta, C. et al. 2003. Potent immune response against HIV-1 and protection from virus challenge in hu-PBLSCID mice immunized with inactivated virus-pulsed dendritic cells generated in the presence of IFN-alpha. J. Exp. Med. 198: 361-367.
19. Lapenta, C. et al. 2006. IFN-alpha-conditioned dendritic cells are highly efficient in inducing cross-priming CD8(+) T cells against exogenous viral antigens. Eur. J. Immunol. 36: 2046-2060.
20. Le Bon, A. et al. 2001.Type i interferons potently enhance humoral immunity and can promote isotype switching by stimulating dendritic cells in vivo. Immunity 14: 461-470.
21. Belardelli, F. et al. 2002. Interferon-alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 13: 119-134.
22. Rizza, P. et al. 2008. Evaluation of the effects of human leukocyte IFN-alpha on the immune response to the HBV vaccine in healthy unvaccinated individuals. Vaccine 26: 1038-1049.
23. Miquilena-Colina, M.E. et al. 2009. Recombinant interferon-alpha2b improves immune response to hepatitis B vaccination in haemodialysis patients: results of a randomised clinical trial. Vaccine 27: 5654-5660.
24. Di Pucchio, T. et al. 2006. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer Res. 66: 4943-4951.
25. Gogas, H. et al. 2006. Prognostic significance of autoimmunity during treatment of melanoma with interferon. N. Engl. J. Med. 354: 709-718.
26. Kirkwood, J.M. et al. 2009. Immunogenicity and antitumor effects of vaccination with peptide vaccine+/- granulocyte-monocyte colony-stimulating factor and/or IFN-alpha2b in advancedmetastaticmelanoma: Eastern Cooperative Oncology Group Phase II Trial E1696. Clin. Cancer Res. 15: 1443-1451.
27. Gogas, H. & J.M. Kirkwood. 2009. Predictors of response to interferon therapy. Curr. Opin. Oncol. 21: 138-143.
28. Maguire, H.C., Jr. & V.L. Ettore. 1967. Enhancement of dinitrochlorobenzene (DNCB) contact sensitization by cyclophosphamide in the guinea pig. J. Invest. Dermatol. 48: 39-43.
29. Rosenberg, S.A., P. Spiess & R. Lafreniere. 1986. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 233: 1318-1321.
30. Awwad, M. & R.J.North. 1988.Cyclophosphamide (Cy)- facilitated adoptive immunotherapy of a Cy-resistant tumour. Evidence that Cy permits the expression of adoptive T-cell mediated immunity by removing suppressor T cells rather than by reducing tumour burden. Immunology 65: 87-92.
31. Garaci, E. et al. 1990. Combination treatment using thymosin alpha 1 and interferon after cyclophosphamide is able to cure Lewis lung carcinoma in mice. Cancer Immunol. Immunother. 32: 154-160.
32. Garaci, E. et al. 1993. Antitumor effect of thymosin alpha 1/interleukin-2 or thymosin alpha 1/interferon alpha, beta following cyclophosphamide in mice injected with highly metastatic Friend erythroleukemia cells. J. Immunother. Emphasis. Tumor Immunol. 13: 7-17.
33. Pica, F. et al. 1998. High doses of thymosin alpha 1 enhance the anti-tumor efficacy of combination chemoimmunotherapy for murine B16 melanoma. Anticancer Res. 18: 3571-3578.
34. Nowak, A.K., R.A. Lake & B.W. Robinson. 2006. Combined chemoimmunotherapy of solid tumours: improving vaccines? Adv. Drug Deliv. Rev. 58: 975-990.
35. Dummer,W. et al. 2002. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J. Clin. Invest. 110: 185-192.
36. Proietti, E. et al. 1998. Importance of cyclophosphamideinduced bystander effect on T cells for a successful tumor eradication in response to adoptive immunotherapy in mice. J. Clin. Invest. 101: 429-441.
37. Vierboom, M.P. et al. 2000. Cyclophosphamide enhances anti-tumor effect of wild-type p53-specific CTL. Int. J. Cancer 87: 253-260.
38. Machiels, J.P. et al. 2001. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 61: 3689-3697.
39. Dudley, M.E. et al. 2002. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 298: 850-854.
40. Schiavoni, G. et al. 2000. Cyclophosphamide induces type I interferon and augments the number of CD44(hi) T lymphocytes in mice: implications for strategies of chemoimmunotherapy of cancer. Blood 95: 2024-2030.
41. Hermans, I.F. et al. 2003. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model. Cancer Res. 63: 8408-8413.
42. Matar, P. et al. 2002. Th2/Th1 switch induced by a single low dose of cyclophosphamide in a rat metastatic lymphoma model. Cancer Immunol. Immunother. 50: 588-596.
43. Ghiringhelli, F. et al. 2004. CD4+CD25 +regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Eur. J. Immunol. 34: 336-344.
44. Lutsiak, M.E. et al. 2005. Inhibition of CD4(+)25+ T regulatory cell function implicated in enhanced immune response by low-dose cyclophosphamide. Blood 105: 2862-2868.
45. Bracci, L. et al. 2007. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells through the induction of cytokine expression, Bcell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin. Cancer Res. 13: 644-653.
46. Gattinoni, L. et al. 2005. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 202: 907-912.
47. Salem, M.L. et al. 2007. Defining the ability of cyclophosphamide preconditioning to enhance the antigenspecific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. J. Immunother. 30: 40-53.
48. Radojcic, V. et al. 2009. Cyclophosphamide resets dendritic cell homeostasis and enhances antitumor immunity through effects that extend beyond regulatory T cell elimination. Cancer Immunol. Immunother.
49. Van Der Most, R.G. et al. 2008. Decoding dangerous death: how cytotoxic chemotherapy invokes inflammation, immunity or nothing at all. Cell Death Differ. 15: 13-20.
50. Green, D.R. et al. 2009. Immunogenic and tolerogenic cell death. Nat. Rev. Immunol. 9: 353-363.
51. Casares, N. et al. 2005. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J. Exp. Med. 202: 1691-1701.
52. Berd, D., H.C. Maguire, Jr. & M.J. Mastrangelo. 1986. Induction of cell-mediated immunity to autologous melanoma cells and regression of metastases after treatment with a melanoma cell vaccine preceded by cyclophosphamide. Cancer Res. 46: 2572-2577.
53. Bystryn, J.C. et al. 1988. Immunogenicity of a polyvalent melanoma antigen vaccine in humans. Cancer 61: 1065-1070.
54. Berd, D. et al. 1990. Treatment of metastatic melanoma with an autologous tumor-cell vaccine: clinical and immunologic results in 64 patients. J. Clin. Oncol. 8: 1858-1867.
55. Livingston, P.O. et al. 1994. Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside. J. Clin. Oncol. 12: 1036-1044.
56. Vaishampayan, U. et al. 2002. Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha. Clin. Cancer Res. 8: 3696-3701.
57. Hoon, D.S. et al. 1990. Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide. Cancer Res. 50: 5358-5364.
58. Ghiringhelli, F. et al. 2007. Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol. Immunother. 56: 641-648.
59. Dudley, M.E. et al. 2005. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J. Clin. Oncol. 23: 2346-2357.
60. Dudley, M.E. et al. 2008. Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens. J. Clin. Oncol. 26: 5233-5239.
61. North, S.A. et al. 2006. A pilot study of the liposomal MUC1vaccineBLP25 in prostate specific antigen failures after radical prostatectomy. J. Urol. 176: 91-95.
62. MacLean, G.D. et al. 1996. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J. Immunother. Emphasis Tumor Immunol. 19: 309-316.
63. Gonzalez, G. et al. 2003. Epidermal growth factor-based cancer vaccine for non-small-cell lung cancer therapy. Ann. Oncol. 14: 461-466.
64. Neninger, E. et al. 2009. Combining an EGF-based cancer vaccine with chemotherapy in advanced nonsmall cell lung cancer. J. Immunother. 32: 92-99.
65. Holtl, L. et al. 2005. Allogeneic dendritic cell vaccination against metastatic renal cell carcinoma with or without cyclophosphamide. Cancer Immunol. Immunother. 54: 663-670.
66. Nistico, P. et al. 2009. Chemotherapy enhances vaccineinduced antitumor immunity inmelanoma patients. Int. J. Cancer. 124: 130-139.
67. Tong, Y., W. Song & R.G. Crystal. 2001. Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. Cancer Res. 61: 7530-7535.